Summary: Evaluated irbesartan versus placebo in patients with heart failure and ejection fractions of > 45%. The primary endpoint of composite death from any cause or hospitalization for specified cardiovascular causes was not reduced. There was no benefit in any subgroup.
N Engl J Med. 2008 Dec 4;359(23):2456-67.
Eponym: Irbesartan in Patients with Heart Failure and PRESERVEd Ejection Fraction